Cellectar Biosciences, Inc. financial data

Symbol
CLRB on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Campus Drive, Florham Park, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
NOVELOS THERAPEUTICS, INC. (to 2/11/2014), COMMON HORIZONS INC (to 6/2/2005)
Latest financial report
10-Q - Q3 2024 - Nov 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 129 % +41.8%
Debt-to-equity 367 %
Return On Equity -805 % -214%
Return On Assets -165 % +43.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40.6M shares +230%
Common Stock, Shares, Outstanding 40.6M shares +309%
Entity Public Float 18.9M USD -22.2%
Common Stock, Value, Issued 406 USD +310%
Weighted Average Number of Shares Outstanding, Basic 39.3M shares +248%
Weighted Average Number of Shares Outstanding, Diluted 39.8M shares +252%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 27.7M USD +11.8%
General and Administrative Expense 23.9M USD +163%
Costs and Expenses 51.6M USD +52.4%
Operating Income (Loss) -51.6M USD -52.4%
Nonoperating Income (Expense) 1.41M USD +83.5%
Net Income (Loss) Attributable to Parent -50.1M USD -5.94%
Earnings Per Share, Basic -1.72 USD/shares +61.2%
Earnings Per Share, Diluted -1.9 USD/shares +57.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 34.3M USD +80.5%
Assets, Current 35.9M USD +78.5%
Property, Plant and Equipment, Net 910K USD +1.86%
Operating Lease, Right-of-Use Asset 454K USD -12.3%
Other Assets, Noncurrent 29.8K USD 0%
Assets 37.3M USD +73%
Accounts Payable, Current 5.62M USD +120%
Liabilities, Current 20.3M USD -31.9%
Operating Lease, Liability, Noncurrent 432K USD -15.8%
Liabilities 20.7M USD -31.6%
Retained Earnings (Accumulated Deficit) -245M USD -25.7%
Stockholders' Equity Attributable to Parent 15.2M USD
Liabilities and Equity 37.3M USD +73%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.4M USD -86%
Net Cash Provided by (Used in) Financing Activities 43.8M USD
Net Cash Provided by (Used in) Investing Activities -21.6K USD
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 40.6M shares +309%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 30.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.3M USD +80.5%
Deferred Tax Assets, Valuation Allowance 87.9M USD +20.6%
Deferred Tax Assets, Gross 88.1M USD +20.5%
Operating Lease, Liability 513K USD -9.84%
Payments to Acquire Property, Plant, and Equipment 21.6K USD
Lessee, Operating Lease, Liability, to be Paid 693K USD -15.9%
Property, Plant and Equipment, Gross 1.98M USD +77.8%
Operating Lease, Liability, Current 80.8K USD +43.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 150K USD +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 146K USD +317%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 180K USD -29.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 153K USD +4.08%
Preferred Stock, Shares Issued 111 shares 0%
Preferred Stock, Shares Authorized 1.23K shares -82.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 155K USD +3.33%
Additional Paid in Capital 247M USD +47.7%
Preferred Stock, Shares Outstanding 111 shares 0%
Depreciation, Depletion and Amortization 88.5K USD +108%
Deferred Tax Assets, Net of Valuation Allowance 87.9M USD +20.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%